EDITORIAL
Asthma: ICS as a rescue approach - following the patients’ preferences
 
More details
Hide details
1
2nd Department of Respiratory Medicine, Medical School of National and Kapodistrian University of Athens, “Attikon” Hospital, Athens, Greece
 
2
1st Department of Respiratory Medicine, Medical School of National and Kapodistrian University of Athens, «Sotiria» Hospital of Chest Diseases, Athens, Greece
 
 
Corresponding author
Stelios Loukides   

2nd Department of Respiratory Medicine, Medical School of National and Kapodistrian University of Athens, “Attikon” Hospital, 1 Rimini street, 12562, Athens, Greece
 
 
Pneumon 2019;32(4):127-129
 
KEYWORDS
CONFLICTS OF INTEREST
No conflicts of interest to declare.
FUNDING
No funding.
 
REFERENCES (16)
1.
Global Initiative for Asthma. Global strategy for asthma management and prevention. 2019. Available from: www.ginasthma.org. Accessed 10 July 2019.
 
2.
Stanford RH, Shah MB, D’Souza AO, Dhamane AD, Schatz M. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol 2012; 109:403-7.
 
3.
Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994;149:604–10.
 
4.
Papi A, Caramori G, Adcock IM, Barnes PJ. Rescue treatment in asthma: more than as-needed bronchodilation. Chest 2009; 135:1628-33.
 
5.
Beasley R, Weatherall M, Shirtcliffe P, Hancox R, Reddel HK. Combination corticosteroid/β-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma? J Allergy Clin Immunol 2014;133:39-41.
 
6.
O’Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: time for a new approach? Eur Respir J 2017; 50:1701103-1701103.
 
7.
Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007;356:2040–52.
 
8.
O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med 2018;378:1865–76.
 
9.
Bateman ED, Reddel HK, O’Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378:1877–87.
 
10.
Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med 2019;380:2020–30.
 
11.
Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet 2019.
 
12.
Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest 2006;130(Suppl):S65-S72.
 
13.
Jónasson G, Carlsen KH, Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child 2000;83:330-3.
 
14.
Dusser D, Montani D, Chanez P, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy 2007;62:591-604.
 
15.
Muneswarao J, Hassali MA, Ibrahim B, Saini B, Hyder Ali IA, Verma AK. It is time to change the way we manage mild asthma: an update in GINA 2019. Respir Res 2019;20:183.
 
16.
Domingo C, Jordi R, Sogo A. As-needed ICS-LABA in mild asthma: What does the evidence say? Drugs 2019; 79.16: 1729-37.
 
eISSN:1791-4914
ISSN:1105-848X
Journals System - logo
Scroll to top